Linked Life Data

15476595

Source:http://linkedlifedata.com/resource/pubmed/id/15476595

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:15476595rdf:typepubmed:Citationlld:pubmed
pubmed-article:15476595lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:15476595lifeskim:mentionsumls-concept:C0006754lld:lifeskim
pubmed-article:15476595lifeskim:mentionsumls-concept:C0006826lld:lifeskim
pubmed-article:15476595lifeskim:mentionsumls-concept:C0013216lld:lifeskim
pubmed-article:15476595lifeskim:mentionsumls-concept:C1513822lld:lifeskim
pubmed-article:15476595lifeskim:mentionsumls-concept:C0008976lld:lifeskim
pubmed-article:15476595lifeskim:mentionsumls-concept:C0684249lld:lifeskim
pubmed-article:15476595lifeskim:mentionsumls-concept:C1880171lld:lifeskim
pubmed-article:15476595lifeskim:mentionsumls-concept:C0045093lld:lifeskim
pubmed-article:15476595lifeskim:mentionsumls-concept:C0205390lld:lifeskim
pubmed-article:15476595lifeskim:mentionsumls-concept:C0332293lld:lifeskim
pubmed-article:15476595lifeskim:mentionsumls-concept:C1514162lld:lifeskim
pubmed-article:15476595pubmed:issue2lld:pubmed
pubmed-article:15476595pubmed:dateCreated2004-10-12lld:pubmed
pubmed-article:15476595pubmed:abstractTextA phase II trial was designed to evaluate the efficacy and toxicity of gemcitabine in patients with non-small-cell lung cancer (NSCLC) previously treated with platinum-containing regimens and prospectively categorized for platinum response status. Treatment consisted of gemcitabine 1000 mg/m2 given intravenously on days 1 and 8 of a 21-day cycle. The status of p53 in pretreatment tumor tissue was assessed by immunohistochemistry (IHC). Sixty-one patients who progressed or recurred following platinum-based therapy were enrolled, 26 platinum-sensitive and 35 platinum-refractory. A median of 4 treatment courses (range, 2-7 courses) was delivered. Of the 55 patients assessable for response, there was 1 confirmed complete response and 3 with a confirmed partial response for an overall response proportion of 7%. Twenty-one patients had stable disease while 28 progressed and 2 patients had an unconfirmed partial response. Three of the responders (2 confirmed, 1 unconfirmed) were platinum-refractory. Median progression-free survival (PFS) and overall survival for all patients were 4.1 months and 8.6 months, respectively. Median PFS and overall survival for the platinum-sensitive and platinum-refractory cohorts were 5.4 months versus 3.1 months, and 11.9 months versus 7.1 months, respectively. Toxicity was principally hematologic with grade 3/4 neutropenia in 21% and grade 4 platelets in 8%. There were no treatment-related deaths. Twenty-four of 33 patients (73%) had p53-positive tumors. Although no significant association between platinum sensitivity and p53 status was seen, patients with platinum-sensitive disease and negative p53 by IHC had a trend toward longer survival compared to those with platinum-refractory disease and/or p53 positivity (P = 0.06). We concluded that salvage gemcitabine in this dose and schedule is safe and tolerable in previously platinum-treated patients with NSCLC.lld:pubmed
pubmed-article:15476595pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15476595pubmed:languageenglld:pubmed
pubmed-article:15476595pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15476595pubmed:citationSubsetIMlld:pubmed
pubmed-article:15476595pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15476595pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15476595pubmed:statusMEDLINElld:pubmed
pubmed-article:15476595pubmed:monthSeplld:pubmed
pubmed-article:15476595pubmed:issn1525-7304lld:pubmed
pubmed-article:15476595pubmed:authorpubmed-author:GandaraDavid...lld:pubmed
pubmed-article:15476595pubmed:authorpubmed-author:LaraPrimo...lld:pubmed
pubmed-article:15476595pubmed:authorpubmed-author:LauDerick H...lld:pubmed
pubmed-article:15476595pubmed:authorpubmed-author:GumerlockPaul...lld:pubmed
pubmed-article:15476595pubmed:authorpubmed-author:FrankelPaulPlld:pubmed
pubmed-article:15476595pubmed:authorpubmed-author:EdelmanMartin...lld:pubmed
pubmed-article:15476595pubmed:authorpubmed-author:DoroshowJames...lld:pubmed
pubmed-article:15476595pubmed:authorpubmed-author:AlbainKathy...lld:pubmed
pubmed-article:15476595pubmed:authorpubmed-author:Gandour-Edwar...lld:pubmed
pubmed-article:15476595pubmed:authorpubmed-author:LongmateJeffJlld:pubmed
pubmed-article:15476595pubmed:authorpubmed-author:IsraelValerie...lld:pubmed
pubmed-article:15476595pubmed:authorpubmed-author:MackPhilip...lld:pubmed
pubmed-article:15476595pubmed:authorpubmed-author:LawLisa YLYlld:pubmed
pubmed-article:15476595pubmed:authorpubmed-author:ReddyGayatri...lld:pubmed
pubmed-article:15476595pubmed:issnTypePrintlld:pubmed
pubmed-article:15476595pubmed:volume6lld:pubmed
pubmed-article:15476595pubmed:ownerNLMlld:pubmed
pubmed-article:15476595pubmed:authorsCompleteYlld:pubmed
pubmed-article:15476595pubmed:pagination102-7lld:pubmed
pubmed-article:15476595pubmed:dateRevised2008-12-12lld:pubmed
pubmed-article:15476595pubmed:meshHeadingpubmed-meshheading:15476595...lld:pubmed
pubmed-article:15476595pubmed:meshHeadingpubmed-meshheading:15476595...lld:pubmed
pubmed-article:15476595pubmed:meshHeadingpubmed-meshheading:15476595...lld:pubmed
pubmed-article:15476595pubmed:meshHeadingpubmed-meshheading:15476595...lld:pubmed
pubmed-article:15476595pubmed:meshHeadingpubmed-meshheading:15476595...lld:pubmed
pubmed-article:15476595pubmed:meshHeadingpubmed-meshheading:15476595...lld:pubmed
pubmed-article:15476595pubmed:meshHeadingpubmed-meshheading:15476595...lld:pubmed
pubmed-article:15476595pubmed:meshHeadingpubmed-meshheading:15476595...lld:pubmed
pubmed-article:15476595pubmed:meshHeadingpubmed-meshheading:15476595...lld:pubmed
pubmed-article:15476595pubmed:meshHeadingpubmed-meshheading:15476595...lld:pubmed
pubmed-article:15476595pubmed:meshHeadingpubmed-meshheading:15476595...lld:pubmed
pubmed-article:15476595pubmed:meshHeadingpubmed-meshheading:15476595...lld:pubmed
pubmed-article:15476595pubmed:meshHeadingpubmed-meshheading:15476595...lld:pubmed
pubmed-article:15476595pubmed:meshHeadingpubmed-meshheading:15476595...lld:pubmed
pubmed-article:15476595pubmed:meshHeadingpubmed-meshheading:15476595...lld:pubmed
pubmed-article:15476595pubmed:meshHeadingpubmed-meshheading:15476595...lld:pubmed
pubmed-article:15476595pubmed:meshHeadingpubmed-meshheading:15476595...lld:pubmed
pubmed-article:15476595pubmed:meshHeadingpubmed-meshheading:15476595...lld:pubmed
pubmed-article:15476595pubmed:meshHeadingpubmed-meshheading:15476595...lld:pubmed
pubmed-article:15476595pubmed:meshHeadingpubmed-meshheading:15476595...lld:pubmed
pubmed-article:15476595pubmed:year2004lld:pubmed
pubmed-article:15476595pubmed:articleTitleGemcitabine in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy: a phase II California cancer consortium trial.lld:pubmed
pubmed-article:15476595pubmed:affiliationUniversity of California Davis Cancer Center, Sacramento, CA 95817, USA. primo.lara@ucdmc.ucdavis.edu.lld:pubmed
pubmed-article:15476595pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:15476595pubmed:publicationTypeClinical Triallld:pubmed
pubmed-article:15476595pubmed:publicationTypeComparative Studylld:pubmed
pubmed-article:15476595pubmed:publicationTypeResearch Support, U.S. Gov't, P.H.S.lld:pubmed
pubmed-article:15476595pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
pubmed-article:15476595pubmed:publicationTypeClinical Trial, Phase IIlld:pubmed